Moderna Shares Surge Over 176% on Positive Phase 3 Melanoma Trial Data
On August 19, Moderna (NASDAQ: MRNA) saw its stock price surge by over 176%, closing at $174.38 per share after the company and Merck reported positive results from a Phase 3 clinical trial for their melanoma treatment combination. The therapy involved Moderna’s intismeran autogene paired with Merck's KEYTRUDA, marking Moderna's first individualized neoantigen therapy (INT) to show meaningful improvements over existing treatments. The stock surge significantly increased Moderna's market cap from $25 billion to $69 billion. The trial success has sparked investor interest in the potential for broader applications of intismeran across other ongoing cancer trials, suggesting significant growth opportunities for the company. Trading volume was notably high at 185.1 million shares, far exceeding its three-month average. The S&P 500 and Nasdaq Composite also saw modest gains on the day as biotech stocks like BioNTech SE and Pfizer rose in value.
Topics: biotech cancer_treatment mRNA_therapies Phase-3-trials